Company / Return on Assets (ROA)
Tarsus Pharmaceuticals, Inc. Return on Assets (ROA) History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Assets (ROA)
-11.8%
FY2025
5-year range
-51.2% / -6.1%
FY2021-FY2025
Trend
+61.5%
vs FY2024
Sector context
#88 of 213
Health Care
What the data says
At -11.8%, Tarsus Pharmaceuticals, Inc.'s return on assets (roa) ranks #88 of 213 in the Health Care sector. Return on Assets (ROA) has fluctuated over the past 7 years, ranging from -51.2% in FY2023 to -6.1% in FY2022.
Based on SEC 10-K filings.
-11.8% in FY2025 with a 5-year CAGR of +3.8%.
Improved from -51.2% to -11.8% over the past 2 years.
Health Care sector context is included.
Return on Assets (ROA) over time
Growth rates
- 3-Year Change
- -5.7pp
- 5-Year Change
- +3.8pp
- 10-Year Change
- -
Sector benchmark
#88 of 213 in Health CareTop 41% of 213This company -11.8% Sector average -24.1%
▼
+51.1% above sector average
Key checks
Key Insights
- In FY2025, return on assets (roa) increased 61.5% year-over-year.
- Currently 12.3pp above the Health Care sector average.
- Peak return on assets (roa) was recorded in FY2022.
- Lowest return on assets (roa) in the period was in FY2023.
Company context
Key Data Points
- Altman Z-Score 0.92 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Assets (ROA)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -11.8% | +61.5% |
| FY2024 | -30.6% | +40.1% |
| FY2023 | -51.2% | -743.3% |
| FY2022 | -6.1% | +21.5% |
| FY2021 | -7.7% | +50.4% |
| FY2020 | -15.6% | -94.6% |
| FY2019 | -8.0% | - |
| FY2018 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026